| 14.94 -0.4 (-2.61%) | 05-05 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |   |
|||
| Targets | 6-month : | 18.55 | 1-year : | 21.66 |
| Resists | First : | 15.88 | Second : | 18.55 |
| Pivot price | 13.94 |
|||
| Supports | First : | 13.74 | Second : | 12.42 |
| MAs | MA(5) : | 13.92 |
MA(20) : | 14.12 |
| MA(100) : | 12.82 |
MA(250) : | 9.88 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 64.4 |
D(3) : | 45.4 |
| RSI | RSI(14): 58 |
|||
| 52-week | High : | 16.73 | Low : | 5.67 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ CGEM ] has closed below upper band by 21.9%. Bollinger Bands are 14.7% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 15.76 - 15.84 | 15.84 - 15.89 |
| Low: | 14.03 - 14.13 | 14.13 - 14.19 |
| Close: | 14.79 - 14.95 | 14.95 - 15.05 |
Cullinan Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the developing of oncology and immuno-oncology therapies. Its pipeline includes CLN-978, CLN-619, Zipalertinib CLN-081/TAS6417, CLN-049, and CLN-617. The company was founded by Patrick A. Baeuerle on September 15, 2016 and is headquartered in Cambridge, MA.
Tue, 05 May 2026
Insider sales at CGEM (NASDAQ: CGEM) include 8,000-share 10b5-1 trade - Stock Titan
Tue, 05 May 2026
Cullinan Therapeutics (NASDAQ:CGEM) Shares Down 5.6% - Time to Sell? - MarketBeat
Tue, 05 May 2026
Cullinan Therapeutics, Inc. (NASDAQ:CGEM) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
Mon, 04 May 2026
Cullinan Therapeutics (NASDAQ:CGEM) Trading 8.5% Higher - Here's Why - MarketBeat
Thu, 30 Apr 2026
Cullinan Therapeutics: Cash-Rich With A Major 2027 FDA Catalyst (NASDAQ:CGEM) - Seeking Alpha
Wed, 29 Apr 2026
Cullinan wins FDA review for cancer therapy developed with Taiho - MSN
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Pharmaceuticals
|
|
| Shares Out | 61 (M) |
| Shares Float | 43 (M) |
| Held by Insiders | 0.4 (%) |
| Held by Institutions | 105.7 (%) |
| Shares Short | 8,110 (K) |
| Shares Short P.Month | 8,360 (K) |
| EPS | -3.36 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 6.78 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -28.3 % |
| Return on Equity (ttm) | -44.1 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -3.93 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -176 (M) |
| Levered Free Cash Flow | -100 (M) |
| PE Ratio | -4.45 |
| PEG Ratio | 0 |
| Price to Book value | 2.2 |
| Price to Sales | 0 |
| Price to Cash Flow | -5.23 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|